Search

Your search keyword '"Lamm, Wolfgang"' showing total 280 results
Start Over Author "Lamm, Wolfgang"
280 results on '"Lamm, Wolfgang"'

2. Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial

Author

Mair, Maximilian J., Maj-Hes, Agnieszka, Nussbaumer-Pröll, Alina, Puhr, Rainer, Christenheit, Agnieszka, Troch, Marlene, Puhr, Hannah C., Starzer, Angelika M., Steindl, Ariane, Eberl, Sabine, Haslacher, Helmuth, Perkmann, Thomas, Minichsdorfer, Christoph, Prager, Gerald W., Lamm, Wolfgang W., Berghoff, Anna S., Kiesewetter, Barbara, Zeitlinger, Markus, Preusser, Matthias, and Raderer, Markus

Published
2023
Full Text
View/download PDF

7. Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field

Author

Marhold, Maximilian, Topakian, Thais, Agis, Hermine, Bartsch, Rupert, Berghoff, Anna S., Brodowicz, Thomas, Fuereder, Thorsten, Ilhan-Mutlu, Aysegül, Kiesewetter, Barbara, Krainer, Michael, Locker, Gottfried J., Marosi, Christine, Prager, Gerald, Schmidinger, Manuela, Thallinger, Christiane, Zöchbauer-Müller, Sabine, Raderer, Markus, Preusser, Matthias, and Lamm, Wolfgang

Published
2020
Full Text
View/download PDF

12. Chemotherapy With Eribulin Following Potentially Curative Surgery in Patients With Localized Liposarcoma.

Author

STEINBRECHER, OSKAR, BRODOWICZ, THOMAS, POPOV, PETAR, and LAMM, WOLFGANG

Subjects
LIPOSARCOMA, CANCER chemotherapy, ERIBULIN, SOFT tissue tumors, SURGICAL excision
Abstract

Background/Aim: Soft tissue sarcomas are rare and heterogenous malignancies with high recurrence rates following resection and a poor prognosis in advanced stages. Eribulin is used in metastatic soft tissue sarcoma patients, who have failed first line chemotherapy and has been approved for patients with pretreated advanced liposarcoma (LPS) in the United States and Europe following the publication of data of a phase III trial. In addition, no data are available for eribulin as postoperative treatment after potentially curative surgery. We, thus, retrospectively evaluated efficacy and tolerability of adjuvant eribulin in patients with LPS not suitable for intensive chemotherapy in the routine clinical setting. Patients and Methods: In this retrospective single center analysis, efficacy and safety of eribulin were retrospectively evaluated in five high risk LPS patients. Results: Eribulin as treatment was administered to five patients with LPS following surgical resection. Median progression-free survival and overall survival were 12.3 months and 44.3 months, respectively. Toxicity was generally manageable, and grade 3+4 events were rare. Conclusion: Postoperative eribulin may be feasible in selected high risk LPS patients, who are not candidates for intensive chemotherapy regimens. Further prospective trials, however, are needed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron

Author

Mair, Maximilian J., Mitterer, Manfred, Gattinger, Pia, Berger, Julia M., Trutschnig, Wolfgang, Bathke, Arne C., Gansterer, Margaretha, Berghoff, Anna S., Laengle, Severin, Gottmann, Lynn, Buratti, Thomas, Haslacher, Helmuth, Lamm, Wolfgang W., Raderer, Markus, Tobudic, Selma, Fuereder, Thorsten, Valenta, Rudolf, Fong, Dominic, and Preusser, Matthias

Published
2022
Full Text
View/download PDF

23. Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study

Author

Mair, Maximilian J., primary, Berger, Julia M., additional, Mitterer, Manfred, additional, Gansterer, Margaretha, additional, Bathke, Arne C., additional, Trutschnig, Wolfgang, additional, Berghoff, Anna S., additional, Perkmann, Thomas, additional, Haslacher, Helmuth, additional, Lamm, Wolfgang W., additional, Raderer, Markus, additional, Tobudic, Selma, additional, Fuereder, Thorsten, additional, Buratti, Thomas, additional, Fong, Dominic, additional, and Preusser, Matthias, additional

Published
2022
Full Text
View/download PDF

26. Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations

Author

Mair, Maximilian J., primary, Berger, Julia M., additional, Berghoff, Anna S., additional, Starzer, Angelika M., additional, Ortmayr, Gregor, additional, Puhr, Hannah C., additional, Steindl, Ariane, additional, Perkmann, Thomas, additional, Haslacher, Helmuth, additional, Strassl, Robert, additional, Tobudic, Selma, additional, Lamm, Wolfgang W., additional, Raderer, Markus, additional, Mitterer, Manfred, additional, Fuereder, Thorsten, additional, Fong, Dominic, additional, and Preusser, Matthias, additional

Published
2022
Full Text
View/download PDF

30. Eribulin in Patients with Liposarcoma and Leiomyosarcoma: A Retrospective Single-Center Experience.

Author

Steinbrecher, Oskar, Brodowicz, Thomas, Raderer, Markus, Scharrer, Anke, Fabsits, Johannes, and Lamm, Wolfgang

Subjects
LEIOMYOSARCOMA, DRUG efficacy, INTRAVENOUS therapy, CONFIDENCE intervals, RETROSPECTIVE studies, ACQUISITION of data, HEALTH outcome assessment, ERIBULIN, MEDICAL records, DESCRIPTIVE statistics, PROGRESSION-free survival, DATA analysis software, ODDS ratio, LIPOSARCOMA, OVERALL survival
Abstract

Introduction: Soft tissue sarcomas are rare and heterogenous malignancies with a poor prognosis in advanced disease stages. Eribulin is used in metastatic liposarcoma (LPS) patients, who have failed first-line chemotherapy and has been approved for use in patients with LPS in the USA and Europe due to its efficacy in this histological subtype in a phase 3 trial. We have evaluated efficacy and tolerability of eribulin in LPS and leiomyosarcoma (LMS) patients in the routine clinical setting at our department. Methods: In this retrospective single-center analysis, efficacy and safety of eribulin were retrospectively evaluated in advanced LPS and LMS patients at the Division of Oncology, Medical University of Vienna. Results: A total of 32 adult patients treated with eribulin were identified and included in this analysis. Overall response rate was 9.4% for all patients, with one patient with LPS and two patients with LMS showing a partial response. Disease control rate (partial response plus stable disease) for all patients was 50% (LPS: 47.1%; LMS 53.3%). No statistically significant difference in median progression-free survival and overall survival was detected between patients with LPS and LMS (p = 0.807 and p = 0.519, respectively). Patients with LMS (n = 2) had received fewer previous therapy lines than patients with LPS (n = 14) (≤ previous treatment lines, p < 0.001). Toxicity was generally manageable, and grade 3 + 4 events were rare. Conclusion: The activity and tolerability of eribulin in LPS as in well in LMS patients in the routine clinical setting is comparable to outcomes reported in published phase 3 trials. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients

Author

Starzer, Angelika M, primary, Berghoff, Anna S, additional, Hamacher, Rainer, additional, Tomasich, Erwin, additional, Feldmann, Katharina, additional, Hatziioannou, Teresa, additional, Traint, Stefan, additional, Lamm, Wolfgang, additional, Noebauer-Huhmann, Iris M, additional, Furtner, Julia, additional, Müllauer, Leonhard, additional, Amann, Gabriele, additional, Bauer, Sebastian, additional, Schildhaus, Hans-Ulrich, additional, Preusser, Matthias, additional, Heller, Gerwin, additional, and Brodowicz, Thomas, additional

Published
2021
Full Text
View/download PDF

37. Incidence and Etiology of System Exchanges in Patients Receiving Extracorporeal Membrane Oxygenation

Author

Nagler, Bernhard, primary, Hermann, Alexander, additional, Robak, Oliver, additional, Schellongowski, Peter, additional, Buchtele, Nina, additional, Bojic, Andja, additional, Schmid, Monika, additional, Zauner, Christian, additional, Winter, Max Paul, additional, Heinz, Gottfried, additional, Ullrich, Roman, additional, Kraft, Felix, additional, Wiedemann, Dominik, additional, Bernardi, Martin H., additional, Staudinger, Thomas, additional, and Lamm, Wolfgang, additional

Published
2021
Full Text
View/download PDF

39. CXCR4 PET imaging of mantle cell lymphoma using [68Ga]Pentixafor: comparison with [18F]FDG-PET

Author

Mayerhoefer, Marius E., primary, Raderer, Markus, additional, Lamm, Wolfgang, additional, Pichler, Verena, additional, Pfaff, Sarah, additional, Weber, Michael, additional, Kiesewetter, Barbara, additional, Hacker, Markus, additional, Kazianka, Lukas, additional, Staber, Philipp B., additional, Wester, Hans-Juergen, additional, Rohrbeck, Johannes, additional, Simonitsch-Klupp, Ingrid, additional, and Haug, Alexander, additional

Published
2021
Full Text
View/download PDF

41. Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI

Author

Taghizadeh, Hossein, primary, Unseld, Matthias, additional, Spalt, Martina, additional, Mader, Robert M., additional, Müllauer, Leonhard, additional, Fuereder, Thorsten, additional, Raderer, Markus, additional, Sibilia, Maria, additional, Hoda, Mir Alireza, additional, Aust, Stefanie, additional, Polterauer, Stephan, additional, Lamm, Wolfgang, additional, Bartsch, Rupert, additional, Preusser, Matthias, additional, A., Kautzky-Willer, additional, and Prager, Gerald W., additional

Published
2020
Full Text
View/download PDF

42. SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic

Author

Berghoff, Anna S., primary, Gansterer, Margaretha, additional, Bathke, Arne C., additional, Trutschnig, Wolfgang, additional, Hungerländer, Philipp, additional, Berger, Julia M., additional, Kreminger, Judith, additional, Starzer, Angelika M., additional, Strassl, Robert, additional, Schmidt, Ralf, additional, Willschke, Harald, additional, Lamm, Wolfgang, additional, Raderer, Markus, additional, Gottlieb, Alex D., additional, Mauser, Norbert J., additional, and Preusser, Matthias, additional

Published
2020
Full Text
View/download PDF

46. Transformed mucosa‐associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction‐based clonality analysis

Author

Kiesewetter, Barbara, primary, Lamm, Wolfgang, additional, Dolak, Werner, additional, Lukas, Julius, additional, Mayerhoefer, Marius E., additional, Weber, Michael, additional, Schiefer, Ana‐Iris, additional, Kornauth, Christoph, additional, Bayer, Günther, additional, Simonitsch‐Klupp, Ingrid, additional, and Raderer, Markus, additional

Published
2019
Full Text
View/download PDF

47. Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma

Author

Vogl Ursula M, Bojic Marija, Lamm Wolfgang, Frischer Josa M, Pichelmayer Oskar, Kramer Gero, Haitel Andrea, Kitz Klaus, Harmankaya Kaan, Zielinski Christoph C, and Schmidinger Manuela

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background In the era of cytokines, patients with brain metastases (BM) from renal cell carcinoma had a significantly shorter survival than patients without. Targeted agents (TA) have improved the outcome of patients with metastatic renal cell carcinoma (mRCC) however, their impact on patients with BM is less clear. The aim of this analysis was to compare the outcome of patients with and without BM in the era of targeted agents. Methods Data from 114 consecutive patients who had access to targeted agent were analyzed for response rates (ORR), progression free survival (PFS) and overall survival (OS). All patients diagnosed with BM underwent local, BM-specific treatment before initiation of medical treatment. Results Data of 114 consecutive patients who had access to at least one type of targeted agents were analyzed. Twelve out of 114 renal cell carcinoma (RCC) patients (10.5%) were diagnosed with BM. Systemic treatment consisted of sunitinib, sorafenib, temsirolimus or bevacizumab. The median PFS was 8.7 months (95% CI 5.1 - 12.3) and 11.4 months (95% CI 8.7 - 14.1) for BM-patients and non-BM-patients, respectively (p = 0.232). The median overall survival for patients with and without BM was 13.4 (95% CI 1- 43.9) and 33.3 months (95% CI 18.6 - 47.0) (p = 0.358), respectively. No patient died from cerebral disease progression. ECOG Performance status and the time from primary tumor to metastases (TDM) were independent risk factors for short survival (HR 2.74, p = 0.001; HR: 0.552, p = 0.034). Conclusions Although extracerebral metastases determine the outcome of patients with BM, the benefit from targeted agents still appears to be limited when compared to patients without BM.

Published
2010
Full Text
View/download PDF

48. Propofol-based sedation does not negatively influence oxygenator running time compared to midazolam in patients with extracorporeal membrane oxygenation

Author

Lamm, Wolfgang, primary, Nagler, Bernhard, additional, Hermann, Alexander, additional, Robak, Oliver, additional, Schellongowski, Peter, additional, Buchtele, Nina, additional, Bojic, Andja, additional, Schmid, Monika, additional, Zauner, Christian, additional, Heinz, Gottfried, additional, Ullrich, Roman, additional, and Staudinger, Thomas, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results